San Francisco-based neurotech startup Coherence Neuro has secured $45 million in seed funding, backed by the OpenAI Startup Fund and Peter Thiel’s Founders Fund. The company is developing brain-computer interface (BCI) technology designed to detect and treat brain tumors, specifically aggressive forms like glioblastoma.

Coherence Neuro’s device records neural signals to identify cancer activity and uses targeted electrical stimulation to disrupt tumor growth. The company completed preliminary safety testing during brain tumor surgeries at Royal Melbourne Hospital and is raising capital to launch long-term human clinical trials.

The investment underscores growing interest from leading AI organizations in obtaining novel neural datasets. By backing hardware startups that generate vast streams of physiological data, AI firms aim to train specialized diagnostic and therapeutic models.

Why it matters

  • Highlights AI labs’ expanding strategic investments into hardware and specialized data generation like brain-computer interfaces.

  • Demonstrates new applications of AI models in real-time biological signal decoding and targeted oncology treatments.

Source: wired.com